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P
ancreatic cysts are being identified with increasing frequency as a result of the escalating use of crosssectional imaging, typically for unrelated reasons. 1, 2 The incidence of pancreatic cysts in the US population is estimated to be between 3% and 15%, with increasing prevalence with age. 3 Identification of a cystic lesion in the pancreas creates anxiety for both patients and clinicians related to the potential specter of a deadly malignancy. Historically, non-neoplastic inflammatory pancreatic pseudocysts were believed to be the most common pancreatic cysts; however, as imaging has become more sensitive, smaller, neoplastic cysts are more frequently detected. The finding of a pancreatic abnormality with potential association with malignancy is an increasing source of referral to specialists and an important driver of resource utilization, particularly in the United States. Imaging studies vary widely in their quality and interpretation, fueling the need for additional investigation. This technical review discusses the challenges in evaluating pancreatic cysts and critically examines the existing data set for evidence-based medical decision making.
Although the concern for current or future malignancy is justified, a rational, evidence-based, cost-effective approach to care of the patient with a pancreatic cyst remains poorly defined. Despite the high prevalence of these lesions, investigators have recently questioned just how frequently a clinically relevant adverse outcome occurs, that is, the development of a life-threatening malignancy. This is a critical consideration given the cost of repeat imaging, performance of invasive procedures such as endoscopic ultrasonography (EUS) with or without fine-needle aspiration (FNA), and consideration of a major pancreatic resection with the substantial attendant morbidity and mortality, particularly in the aging population with a high rate of prevalent cysts. In a recent analysis, investigators using the Surveillance, Epidemiology, and End Results (SEER) database estimated an annual prevalence of 1137 mucin-producing pancreatic adenocarcinomas with a concurrent prevalence of nearly 3.5 million cysts in the same population, concluding that malignant transformation is a very rare event. 4 In this clinical context, the American Gastroenterological Association has commissioned an evidence-based review of the diagnosis and management of pancreatic cysts.
Differential Diagnosis
Cystic lesions of the pancreas have a broad differential diagnosis. In general, they can be categorized into non-neoplastic (eg, pseudocysts) and neoplastic cystic lesions. The latter group, often referred to as cystic neoplasms of the pancreas, can be broadly subcategorized into those that produce a mucin-rich fluid (ie, mucin-producing cystic neoplasms) and those that do not. This distinction is important, because an increased risk of pancreatic adenocarcinoma has been attributed to all of the mucin-producing variants, which include branch duct intraductal papillary mucinous neoplasm (IPMN), main duct IPMN, and mixed IPMN (which has features of branch duct and main duct IPMN). The classic example of a cystic neoplasm that is not mucin producing, to which an increased risk of cancer is not attributed, is a serous cystadenoma. Papillary cystic neoplasms (eg, solid pseudopapillary tumors of the pancreas) and cystic pancreatic neuroendocrine tumors are additional examples of cystic neoplasms of the pancreas. There are many challenges associated with achieving an accurate diagnosis and, arguably more importantly, identifying reliable and reproducible methods to stratify risk of cancer for these patients, making clinical decision making difficult. Several groups, including an international consensus panel, have proposed management recommendations (including algorithms) for patients with suspected cystic neoplasms of the pancreas. 5, 6 These are commonly used in clinical practice; however, these are consensus guidelines and not necessarily evidence based. Following a basic description of the different types of cystic neoplasms, we provide results from our evidence-based systematic literature review, which was designed to assess the strength of the evidence for specific focused clinical questions commonly encountered in the management of patients with pancreatic cysts. The purpose of this report is to assess the existing evidence to address specific clinical questions related to the evaluation and management of pancreatic cysts with a focus on indeterminate cysts.
Pseudocysts
Inflammatory pseudocysts historically were believed to represent up to 90% of all pancreatic cysts, but recent data obtained with high-resolution imaging showed a high prevalence of incidentally noted cysts among patients without a history or evidence of pancreatitis, suggesting that neoplastic cysts are likely far more common. The critical patient management issue is differentiating these nonneoplastic lesions from neoplastic lesions. When a cyst without an associated solid mass arises in a patient with known chronic pancreatitis, the clinical concern of a neoplasm is minimal. When patients present with unexplained pancreatitis for the first time with a cyst, or have only subtle changes of chronic pancreatitis on EUS alone, the clinician should consider whether the cyst may be a neoplasm and the lesion is the cause of the pancreatitis instead of assuming it is the consequence of pancreatitis. Review of imaging studies performed before the episode of pancreatitis, if available, may address this critical question.
Serous Cystadenomas
Serous cystadenomas were originally termed "microcystic adenomas," referring to the small (<2 cm) cystic compartments that make up the tumors. The term "microcystic adenoma" is still used synonymously with serous cystadenomas but has recently been criticized because of reports of macrocystic variants. 7 Serous cystadenomas occur more commonly in women, who typically present in their 60s. Lesions with serous morphology in a young woman or a man may therefore lead to diagnostic confusion. Although nearly always benign, malignant serous cystadenocarcinomas have rarely been described. 8 They can become symptomatic by increasing in size with "invasive features," leading to the recommendation by some surgical experts to remove them in younger patients. The low risk of malignancy should forestall the need for frequent surveillance. However, if the diagnosis is not confirmed, or if there is concern for local invasiveness, surveillance and management for these cysts remains controversial.
Serous cystadenomas are generally slow-growing tumors that are symptomatic in less than one-half of patients. The pathology of these tumors shows wellcircumscribed masses enclosed in a fibrous capsule containing numerous small fluid-filled cysts arranged in a classic "honeycomb" pattern. 9 Fibrous bands within the lesions often converge centrally, forming a stellate scar that may calcify, giving a pathognomonic "sunburst" appearance on computed tomography (CT). 10 
Mucinous Cystic Neoplasms
Mucinous cystic neoplasms (MCNs) represent nearly one-half of the tumors removed in contemporary surgical series. MCNs occur almost exclusively in women (>98%) and are generally diagnosed in patients in their 40s and 50s. 11, 12 The patient may present with pain, an abdominal mass, or weight loss, but up to one-third of series report discovery by cross-sectional imaging for unrelated reasons. Ninety percent of cases occur in the pancreatic body or tail. 13 MCNs are characterized by a thick fibrous capsule that encircles the cystic spaces. A characteristic spindle cell stroma containing epithelioid cells similar to ovarian stroma surrounds the tumor. The cyst lining is composed of mucinproducing duct-like cells frequently exhibiting a papillary architecture. However, the epithelial lining may be denuded, leading to misdiagnosis of a "pseudocyst" on limited tissue samples such as operative frozen sections.
The prognosis of MCNs is defined by the presence or absence of invasive adenocarcinoma. Cancer has been described in approximately one-third of operated tumors; these patients have a variable prognosis, with 5-year survival up to 60% after surgery for cancer to poor outcomes similar to those for ductal adenocarcinoma.
14 One explanation for the disparate findings may reflect sampling, because the invasive component may be only a small part of the lesion. communication to the main pancreatic duct can be difficult to determine with imaging techniques, which can make it difficult to differentiate a branch duct IPMN from other cystic lesions such as MCNs or serous cysts. It has been proposed that the side branch type has a better prognosis than the variant that involves the main duct. Surgical resection must consider the extent of intraductal growth to achieve a negative margin to prevent recurrence. In the absence of carcinoma, prognosis is excellent with definitive surgical resection. 16 A patulous papilla at endoscopy extruding mucus is pathognomonic for the main duct variant.
Less Common Neoplastic Cystic Lesions
Cystic pancreatic neuroendocrine tumors are quite rare and may or may not be associated with symptoms of excess hormone production. If clinical or imaging data suggest this as a relevant diagnostic consideration, attempts to confirm the diagnosis by resecting localized disease should be undertaken due to its malignant potential. 17 Papillary cystic tumors of the pancreas have a characteristic appearance on imaging and should not be confused with the far more common lesions that are the focus of this review. The vast majority of papillary cystic neoplasms are found in female patients (w90%), most often in the third decade of life. 18 Although most of these tumors are benign, approximately 15% may be malignant, leading to the recommendation for surgical resection when they are identified. 19 
Clinical Approach
A detailed history to determine if the patient is experiencing symptoms related to the lesion itself or a related condition such as pancreatitis is important. If previous cross-sectional imaging is available, it should be reviewed to determine if the lesion was present and evaluate for change in size or appearance. Most asymptomatic patients have small lesions that do not cause symptoms because of their small size. Although large cysts may cause vague symptoms of pain, obstructive jaundice is uncommon, even for lesions located in the head. Typical symptoms of malignancy, such as weight loss, epigastric/back pain, nausea, vomiting, and severe malaise, are usually absent. Clinical decision making is driven by an understanding of the differential diagnosis of a cyst and, in the case of the asymptomatic patient, its likelihood of causing harm with testing and/or treatment. The fundamental issue to be addressed is whether the cyst is neoplastic or not. If the cyst is neoplastic, what is the risk of malignant progression? More simply stated, is the upfront risk of surgery justified by the long-term risk of malignancy? If so, does it provide a survival benefit to the patient?
Imaging Studies
High-resolution CT using thin sections with both enhanced and unenhanced technique provides detailed information about the structure of the cyst and may provide a presumptive diagnosis if characteristic features are present.
Magnetic resonance imaging (MRI)/magnetic resonance cholangiopancreatography (MRCP) has the potential added advantage of determining communication between the cyst and pancreatic duct as well as lack of ionizing radiation. The presence of a central scar is a highly diagnostic feature of serous lesions but is seen in only 20% of serous cysts.
Despite the high quality of contemporary CT and MRI, their ability to distinguish neoplastic from non-neoplastic cystic pancreatic lesions remains imperfect. Because of this, EUS has emerged as a useful tool in evaluating these lesions because its resolution is superior to that of CT and MRI. Although some enthusiastic reports were able to differentiate benign from malignant neoplastic tumors and from non-neoplastic cysts with an accuracy of >90% based on the endosonographic appearance of the lesion, other reports emphasize that the technique is not sufficiently accurate to differentiate between benign and malignant lesions unless there is evidence of a solid mass or invasive tumor. 20, 21 Further, although EUS is quite sensitive in detection and evaluation of cyst morphology, it is highly operator dependent, as is the performance of all imaging studies.
Overview
This technical review (and the accompanying guideline) was based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. 22 In developing this technical review, the authors first formulated a series of specific questions that were to be answered by the guideline (Appendix 1). The authors then identified the outcomes that were significant to answering each question and rated them as critical or important. Next, the group systematically reviewed and summarized the evidence for each outcome across studies, assessed the quality of evidence for each outcome, and finally integrated the evidence across all the outcomes to answer each specific question. The quality of the evidence was classified into 4 categories: high, moderate, low, and very low. Assessment of the quality for each outcome took into account the study design, risk of bias, inconsistency (or heterogeneity), indirectness, imprecision, and potential publication bias. The GRADE methodology requires clinical questions to be framed in terms of a designated population (P) undergoing a specific intervention or diagnostic test (I) with an explicit comparator (C) and a defined outcome (O) (the so-called PICO format). If the question does not explicitly state a comparator, then the comparison with no intervention is implied. Initially, we outlined a total of 7 PICO questions ( Table 1) . The patient populations with pancreatic cysts were further analyzed for risk of malignancy based on imaging studies, analysis of cyst fluid, and pathological findings. In addition, an analysis of the prevalence of pancreatic cysts in the population was performed, followed by an estimation of the risk of malignant progression of all pancreatic cysts. We used a consensus decision-making process (http://seedsforchange.org.uk/consensus.pdf) to reach unanimous agreement among the 3 authors on all statements. 
Outcomes of Interest
When using the GRADE process, it is important that the outcomes assessed are patient focused. The most important outcome that would benefit a patient with a pancreatic cyst would be to prevent mortality from cystadenocarcinoma. There are no randomized trials or observational studies comparing screening with no screening in patients with a pancreatic cyst that quantify mortality from adenocarcinoma as an outcome. Numerous studies have described the histological findings of pancreatic cysts in patients who have undergone surgery for resection of a concerning lesion. These studies evaluated a highly selected population in whom surgery has been deemed an appropriate intervention and do not reflect the average patient with a pancreatic cyst. Nevertheless, they give an indication of the histopathology identified in those with "concerning" cystic lesions. These reports often suggest that removal of lesions that contain dysplasia is a successful outcome. Dysplasia is a risk factor for progression to malignancy in other tissues, although the majority of patients do not develop invasive cancer. 23 Surgical intervention would be appropriate if there was little risk to the patient, but this is not the case with pancreatic surgery, which carries a risk of morbidity (approximately 20%-40%) and mortality (<1% in high-volume centers). 24, 25 An analogous situation would be Barrett's esophagus, for which current guidelines do not support surgery when dysplasia is found because the risks of surgery outweigh the benefits. 26 Reports on findings in patients undergoing surgery are further complicated by the inclusion of those with carcinoma in situ as "malignancy." Although these lesions are of undoubted major concern, there is a large body of evidence that this histological lesion does not always progress to invasive adenocarcinoma. 27, 28 Indeed, these lesions result in an excess of surgery in other screening programs such as breast cancer, where it is estimated that 70,000 US women each year undergo surgery for a lesion that would not lead to mortality if left alone. 29 This does not mean that surgery is inappropriate for these women because breast surgery still has more benefits than risks, but this may not apply to pancreatic cyst surgery because the morbidity and mortality rates are higher. Other outcomes of interest that may be prevented by surgery are episodes of acute pancreatitis due to mucus plugs and obstructive jaundice by cysts in the head, neck, and uncinate process.
All of these uncertainties mean that there are a limited number of PICO questions with relevant patient outcomes (survival) that can be answered with any directly relevant data. Normally a guideline that uses the GRADE approach would provide a summary of findings table, but this was not possible due to the paucity of data available. This technical review therefore simply outlines the evidence from these surgical series in a narrative manner to provide the risk of invasive malignancy in this select group according to type of cyst. This will indirectly inform the type of pancreatic cyst that is likely to harbor dysplasia or malignancy. We then evaluated the data according to which imaging modality best diagnosed the type of cyst and malignant risk and then conducted systematic reviews of the literature to address risk of malignant progression in pancreatic cysts that would not undergo initial surgery.
Literature Search
The literature search is described in detail in Appendix 1. MEDLINE was searched from 1946 to July 2013, and reports evaluating pancreatic cystic neoplasms were identified by combining the exploded Medical Subject Heading (MeSH) term "pancreatic cyst" with text words that contained "pancrea" (eg, pancreas or pancreatic) and "cyst" that were separated by 2 adjectives (eg, such a search would detect "cyst of the pancreas" and "pancreatic cysts"). This was combined with the set operator "OR" and the exploded MeSH term "pancreatic neoplasm," with a similar text word approach as described in the preceding text to identify other pancreatic neoplasms. Case reports, letters, and non-English language reports were excluded.
A second search was performed to identify diagnostic studies. This identified pancreatic cysts as described in the preceding section combined with MeSH terms and text words that described ultrasonography (including EUS), CT, MRI, and endoscopic retrograde pancreatography (ERCP). Furthermore, reports that identified tumor markers and cyst fluid analysis were also identified with exploded MeSH terms and text words (see Appendix 1 for details).
The first search identified more than 2000 reports and the second search more than 1500 reports, with duplicates excluded. These references were imported into EndNote version 7.0.1 (Thomson Reuters, Philadelphia, PA) and manually assessed for relevance by 2 reviewers (P.M. and Cathy Yuan). The same 2 reviewers also extracted data relevant for the guideline.
Results
The literature search showed that reports are largely retrospective case series; there are no randomized controlled trials. A key limitation of the current literature is that management recommendations are based on knowledge of the specific cyst histology, which rarely can be determined using current imaging and cyst sampling techniques. This highlights the challenges of providing evidencebased recommendations regarding the management of patients with pancreatic cysts.
Imaging Features of Pancreatic Cysts Predictive of Risk of Malignancy
To address which patients to offer surgery versus surveillance once a lesion is identified, the literature was reviewed to identify such predictive features. The evidence for risk factors for malignancy in pancreatic cysts, including size of the pancreatic cyst, dilation of the pancreatic duct, and a solid component associated with the cyst, was reviewed. We focused on studies of imaging features in which surgical resection was performed so that an accurate diagnosis of the presence or absence of malignancy could be established. Studies that retrospectively selected one type of cyst (eg, MCN or IPMN) and evaluated risk factors in that type of cyst were excluded because it is not possible to establish the diagnosis with certainty before surgery. Therefore, only studies that evaluated all pancreatic cysts that were operated on were included in the analysis, which differs from other reviews in this area that have looked at risk factors in IPMNs specifically. 30 Studies with <20 patients were also excluded. We intended to focus on malignant cysts only; however, there were insufficient data in some areas, so we included studies that reported the diagnostic accuracy of imaging studies on both malignant cysts and cysts with high-grade dysplasia (HGD). The review found no evidence that multiple cysts are predictive of risk of malignancy.
Size of cyst >3 cm. We identified 6 studies evaluating 644 patients undergoing surgery that provided information regarding cyst size. [31] [32] [33] [34] [35] [36] Overall, 381 of 644 patients (59%) had a cyst >3 cm, and malignancy was found in 163 of the 381 patients (43%) with a cyst >3 cm compared with 57 of the 263 patients (22%) with a cyst <3 cm. 
Interval Growth in Pancreatic Cysts and Risk of Adenocarcinoma
Analogous to other gastrointestinal premalignant lesions, it would be anticipated that an increase in size of a pancreatic cyst would herald malignant transformation. To address this issue, we evaluated studies that reported on changes in the size of a pancreatic cyst. There were no studies that addressed this issue according to the criteria we set out in the preceding text; therefore, we relaxed the inclusion criteria and allowed any number of patients, but the case series had to include at least one invasive cancer as well as at least one patient with a cyst that had an increase in interval growth and one patient that did not. Using these very broad eligibility criteria, we found 5 eligible studies. [40] [41] [42] [43] [44] These studies are summarized in Table 3 . Two reports 41, 42 are from the same institution but different time periods, so both were included. Another report 45 from the same institution was excluded because it was also from the same institution and the time period overlapped with the other 2 studies. There were a total of 572 patients with pancreatic cysts, and 125 (22%) had an interval growth in cyst size according to the individual definition used in each report. There was some heterogeneity between studies (
), but none of the studies individually showed a statistically significant effect of growth rate on risk of cancer and the pooled result was also not statistically significant (OR, 1.65; 95% CI, 0.52-5.23). It must be emphasized that most reports included any increase in cyst size and malignancy may have been better predicted if a strict definition of increase in size (eg, >50% increase in size) had been used. It is also important to exclude other reasons why a malignant cyst may have been identified. For example, one report 43 noted that all of the malignant cysts that were identified by an increase in size also had a solid component.
There were also 7 studies 25,46-51 that reported an increase in cyst size but did not report any malignancy occurring in these cysts or did not associate malignancy with cyst growth (Table 4) .
Four additional studies 52-55 reported specifically on serous cystic neoplasms in a total of 500 patients. Follow up was for 10 to 12 years, and a total of 132 patients underwent a pancreatic resection during follow-up. An increase in size of the pancreatic cyst was the reason for surgery in 7 patients, but cyst growth was more commonly reported; it was noted in one report that cyst growth was more likely in tumors >4 cm. 54 None of the 132 patients had cystadenocarcinoma.
52-55 Interestingly, one of these studies recommended resection of cysts that doubled in size in <12 years despite not finding any cases of cancer and having one postoperative death. 55 Rate of adenocarcinoma in surgically resected cysts. A key limitation of the literature is that malignancy is not commonly found among surgical series of resection of pancreatic cysts. 12, 56 Although this reflects the goal to prevent cancer, it precludes an assessment of the impact of the intervention given the lack of a comparison group observed over time (ie, surgical resection vs surveillance). This is relevant because removing precancerous lesions in elderly patients may not provide any survival benefit. The benefit of surgery is most evident for pancreatic cysts that are found to harbor invasive malignancy, and we have evaluated this in a review of the literature. Surgical case series that reported on unselected pancreatic cysts where surgery was deemed appropriate and reported both the final diagnosis for type of pancreatic cyst and the presence or absence of invasive malignancy were included. Studies that evaluated only one type of cyst (eg, IPMN) diagnosed after surgery were excluded in this analysis but are discussed later. Studies that combined invasive malignancy with HGD and did not report the results for invasive malignancy only were not included. We did include studies from the same center/group that could have reported on the same patients more than once, provided that this impact was small.
A total of 27 studies were identified that fulfilled our criteria and reported on 2796 patients with surgically resected cysts evaluated for the presence of malignancy. [32] [33] [34] [35] [36] [37] [38] [39] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] Overall, 418 cysts harbored invasive adenocarcinoma, with proportions in each individual study varying between 0 and 32%. The pooled proportion of cysts with invasive adenocarcinoma was 15% (95% CI, 12%-18%), with marked heterogeneity between studies
). There was also funnel plot asymmetry (Begg-Mazumdar test: Kendall s-b ¼ 0.38, P ¼ .0045), suggesting publication bias or other small study effects. However, if only the studies that included more than 100 patients were selected, 32, 33, [35] [36] [37] [38] [59] [60] [61] 63, 64, 66, 68 the pooled proportion with 
suggesting that small study effects were not a major driver of the overall estimate of the proportion of patients with invasive malignancy. Risk of malignancy in patients undergoing surgery: data specific for IPMNs. We have shown that the overall risk of malignancy when a patient undergoes surgery for a pancreatic cyst is approximately 15%. However, this does not identify the risk of malignancy for each type of cyst. We have evaluated this in surgical series that reported on the risk of malignancy in retrospective case series by analyzing their data on IPMNs. Studies with 20 patients and those that evaluated only main duct IPMN were excluded. Only studies that reported the presence or absence of invasive malignancy were evaluated. The diagnosis of carcinoma in situ or HGD was not considered to be an invasive malignancy in this analysis; however, these studies were evaluated separately.
We identified 111 studies involving 10,812 patients with IPMNs identified at surgery that reported on the presence or absence of invasive malignancy. 35, [37] [38] [39] 60, 63, 70, There was significant heterogeneity between studies reporting on the rate of invasive malignancies in IPMNs (Cochran Q test ¼ 626 [df ¼ 110]; P < .0001; I 2 ¼ 82%; 95% CI, 79%-85%), with an overall invasive malignancy rate of 25% (95% CI, 23%-27%) using a random effects model. There was statistically significant funnel plot asymmetry (Begg-Mazumdar test: Kendall s-b ¼ 0.26; P < .0001), suggesting publication bias or other small study effects. However, any effect of this is likely to be small because graphically the data look reasonably symmetrical.
There were 99 studies assessing 9249 patients that evaluated both the invasive malignancy rate as well as HGD and/or carcinoma in situ rates in IPMNs. 32 2 ¼ 88%; 95% CI, 87%-90%), with an overall high-risk lesion rate of 42% (95% CI, 39%-45%) using a random effects model. Conversely, this means that in these 99 studies of 9249 patients, 58% (95% CI, 55%-61%) had low-risk (eg, low-grade dysplasia) or benign lesions. There was statistically significant funnel plot asymmetry (Begg-Mazumdar test: Kendall s-b ¼ À0.18; P ¼ .01), suggesting publication bias or other small study effects. However, any effect of this is likely to be small because graphically the data look reasonably symmetrical. This latter figure needs to be treated with caution because many studies only reported the high-risk group and we inferred that all others were low risk, but this may not be the case.
Risk of malignancy in patients undergoing surgery in cases in which the investigators reported data specifically for MCNs and serous cystic neoplasms. We evaluated the risk of malignancy in MCNs and serous cystic neoplasms in retrospective surgical series that reported on the presence or absence of invasive malignancy in these lesions. Studies with <20 patients and studies that did not use the term "invasive malignancy" were excluded from the analysis. Cases of carcinoma in situ or HGD were not considered to be invasive malignancies and were evaluated separately.
We identified 12 studies involving 603 patients with MCNs identified at surgery. 33, 37, 58, 60, 61, 64, 130, [186] [187] [188] [189] [190] There was significant heterogeneity between studies for proportions of invasive malignancy with MCNs (Cochran Q test ¼ 57 [df ¼ 11]; P < .0001; I 2 ¼ 81%; 95% CI, 66%-88%), with an overall invasive malignancy rate of 15% (95% CI, 9%-22%) using a random effects model. Test for funnel plot asymmetry was statistically significant (Begg-Mazumdar test, P ¼ .02).
There were 5 studies assessing 295 patients that evaluated the proportion of invasive malignancy in serous cystic neoplasms. [191] [192] [193] [194] There was heterogeneity between studies
2 ¼ 52%; 95% CI, 0%-81%), with an overall high-risk lesion rate of 2.2% (95% CI, 0.3%-5.7%) using a random effects model.
Imaging Evaluation
The rationale for invasive testing and serial imaging of patients with pancreatic cysts is that they will develop pancreatic malignancy at a greater rate than the general population. We found no observational data that address this question, so this fundamental assumption remains uncertain. We therefore approached the problem from another perspective and modeled the likely risk of a pancreatic cyst progressing to invasive malignancy and causing death. These data are fundamentally necessary to understand the predictive value of diagnostic testing. For example, for conditions with a low risk of invasive malignancy, Bayesian analysis would indicate that very high levels of diagnostic test accuracy are needed to increase posttest disease probability to a clinically meaningful degree. Therefore, a systematic review to estimate the prevalence of pancreatic cysts in the population and estimate the risk of progression from national cancer statistics on mucinous pancreatic adenocarcinomas was conducted, expanding the approach of Gardner et al. 4 These investigators used the "two most rigorous cross-sectional imaging studies." A more objective approach would be to conduct a systematic review and synthesize all prevalence studies. We have therefore conducted a systematic review to estimate the prevalence of pancreatic cysts in the population.
Overall prevalence of pancreatic cysts in the general population. We identified 7 reports 1, 2, [195] [196] [197] [198] [199] that were eligible for inclusion in the review. The characteristics of the studies are summarized in Table 5 . Six studies that evaluated pancreatic cysts using MRI identified 1021 cysts in 8890 subjects.
The reported prevalence of pancreatic cysts varied between 2% and 38%, with an overall prevalence of 15% (95% CI, 7%-24%). Two studies 1, 199 evaluated pancreatic cysts using CT and found 465 cysts in 20,275 subjects, for an overall prevalence of 3% (95% CI, 2%-3%).
Two studies showed an increase in prevalence with each age band, with a prevalence of 0.5% in those younger than 40 years of age, 25% in those 70 to 79 years of age, and 37% in those 80 years or age or older (Table 5) . 2, 198 These data are consistent with a Japanese autopsy study that found cysts in 19% of those 70 to 79 years of age and in 30% of those 80 to 89 years of age. 200 Five studies reported cyst size of >2 cm in 25,195 subjects. 2, [196] [197] [198] [199] Overall, there were 194 subjects with cysts >2 cm, for an overall prevalence of 0.8% (95% CI, 0.5%-1.1%).
Estimating the risk of malignancy of pancreatic cysts. We applied the approach used by Gardner et al 4 with US population data and SEER cancer statistics. Using the prevalence of cysts from our systematic review and the risk of cystadenocarcinoma or any descriptor of a mucinous pancreatic adenocarcinoma mortality from the SEER cancer database, the overall risk that a pancreatic cyst is malignant at the time of diagnosis is a maximum of 0.01%. If we assume that only those cysts >2 cm have malignant potential, then the risk that a cyst >2 cm is malignant is a maximum of 0.21%. This is reasonably consistent over all age bands, because although the risk of cancer progression increases with age, so does the prevalence of pancreatic cysts. The overall risk of malignancy for pancreatic infiltrating ductal carcinoma using the SEER cancer database is 0.017%, and even if we assume that all pancreatic cancer arises from a cyst of any size, the probability that a cyst harbors malignancy at the time of imaging is 0.25%. This extremely low risk of cancer is based on several assumptions that could overestimate or underestimate risk. Risk could be overestimated because we assumed that only cysts visible on imaging would progress to cancer. Although size of the cyst is a risk factor, the effect is only modest, and it is possible for small cysts not detected by imaging to become malignant. Risk could also be overestimated because the prevalence could be higher than estimated from the systematic review. The screening studies recruited subjects who volunteered for screening. Such subjects are usually more affluent and have more healthy lifestyles, and this "healthy volunteer effect" reduces their risk of many serious pathologies, including cancer. 201 Patients with a pancreatic cyst identified on cross-sectional imaging should undergo further imaging with MRI. Our literature review indicates that accurate initial characterization of the pancreatic cyst as benign or malignant is critical, because the rate of progression of premalignant mucinous lesions is very slow in the absence of features that increase the risk of malignancy. The initial imaging test should be evaluated for its quality and reviewed by a radiologist experienced in the accurate assessment of pancreatic cystic lesions. Additional imaging may be necessary if the initial test, such as CT or MRI, was performed to evaluate an unrelated symptom. Either dedicated pancreatic CT or MRI may be performed based on availability and local expertise, but high-quality MRI with MRCP should be performed if available; it offers improved delineation of IPMNs from other lesions without radiation exposure because it may be able to determine whether there is communication between the cyst and the pancreatic duct. 202 Although there are no prospective studies to confirm this, ERCP is not recommended for evaluation of pancreatic cysts to define ductal communication because this can be determined with MRCP without subjecting the patient to the risk of pancreatitis.
Patients with a pancreatic cyst with concerning features on MRI should undergo further evaluation with EUS and FNA. Although CT and MRI are sensitive for detecting cysts, there is a high rate of misdiagnosis of the etiology of the cyst on cross-sectional imaging even when the operator certainty is high. 203 The need for additional studies, including EUS, on a routine basis is not supported for most cysts based on the results of this systematic review because studies suggest that the risk of invasive malignancy is very low. However, if there are concerning features, the probability of malignancy may increase to an extent that makes further imaging worthwhile. Our analysis suggested that cyst size >3 cm (OR, 2.97; 95% CI, 1.82-4.85) and presence of a solid component (OR, 7.73; 95% CI, 3.38-17.67) increase the probability of a malignant cyst. In addition, a dilated pancreatic duct showed a trend 30 found this to be a risk factor, so we included dilated pancreatic duct as a risk factor for malignancy. If any of these features are identified on cross-sectional imaging, then further investigation with EUS and/or FNA may provide additional information. However, the performance of EUS and/or FNA has not been systematically reviewed in this setting.
Characterization of the cyst fluid. Although EUS morphology alone has limitations regarding definitive diagnosis of pancreatic cysts, aspiration and characterization of the contents of the cyst fluid has shown somewhat greater value in selected patients. 21 EUS-guided aspiration of a cyst is well tolerated and safe in the hands of an experienced operator, with a complication rate of 1% to 2% for bleeding, perforation, or infection. 204 Most experts use periprocedural antibiotics to reduce the risk of infection, limit the number of needle passes, and remove as much fluid as possible to reduce the risk of bacterial inoculation of the fluid. 205 Considerations include the size of the lesion because the volume of aspirate may be very limited for small lesions. The volume of the cyst fluid can be estimated from the size of the cyst by using the formula (4/3)pr 3 , with r representing the radius of the cyst.
EUS can target any solid lesion associated with the cyst as well as apparent mural nodules. Differentiation of such nodules from adherent mucus can be challenging, and the performance of FNA in excluding malignancy in this setting has not been systematically analyzed. 206 Aspirated fluid has been evaluated by cytology and chemical measurements of amylase and tumor markers. Measurement of the carcinoembryonic antigen (CEA) level in cyst fluid is useful in differentiating mucinous from nonmucinous cysts. As previously discussed, mucinous cysts include IPMNs and MCNs, both of which have malignant potential; nonmucinous cysts, such as serous cysts and pseudocysts, have very low or no malignant potential. Unfortunately, the absolute CEA level is not predictive of current or future risk of malignancy. A systematic review of 12 studies with data from 450 patients found cysts with an amylase concentration of <250 U/L were serous or mucinous (not pseudocyst) with a sensitivity of 44% and specificity of 98%. A CEA level <5 ng/mL suggested a pseudocyst or serous lesion with 50% sensitivity and 95% specificity, whereas a CEA level >800 ng/mL suggested a mucinous lesion (sensitivity of 48% and specificity of 98%). A low cancer antigen 19-9 level in the fluid suggested a pseudocyst or serous lesion (sensitivity of 19% and specificity of 98%), 207 but this test is rarely used because it appears to be no better than measurement of CEA level. The largest prospective study concluded that measurement of CEA level was most useful. Using receiver operator curve analysis, the optimal cutoff for CEA level in cyst fluid was determined to be 192 ng/mL. This resulted in a sensitivity of 75% and a specificity of 84% for diagnosing a mucinous cyst. EUS morphology and cytology were also evaluated individually and in combination. Although the combination of EUS morphology, cytology, and CEA level had a higher sensitivity than CEA level alone (91% vs 75%, respectively), the combination had a lower specificity than CEA level alone and had a smaller area under the receiver operator characteristic curve (P < .0001). Therefore, the combination of EUS morphology, cytology, and CEA level did not improve the ability to differentiate between a mucinous and nonmucinous cyst. 208 Cytology. Cytology revealed malignancy in only 48% of mucinous cancers in the systematic review noted in the preceding text. A recent systematic review highlighted the limitation of EUS-FNA-based cytology for differentiating pancreatic cystic lesions, noting major limitations in studies characterized by significant heterogeneity. 209 Combining 11 studies with confirmed histopathology, the pooled sensitivity and specificity for differentiating mucinous from nonmucinous lesions was 0.63 (95% CI, 0.56-0.70) and 0.88 (95% CI, 0.83-0.93), respectively. The positive and negative LRs were 4.46 and 0.46. 209 These performance characteristics mandate the selective use of EUS with FNA to obtain a specimen if the purpose of FNA is to confirm if the cyst is mucinous, with the understanding that negative cytology has a poor negative predictive value. Although performance of cytology in confirming malignancy is reportedly higher, the studies are limited by selection bias in that only resected lesions are reported. However, it remains reasonable to perform FNA on solid lesions associated with a cyst to determine if a malignancy is present.
Molecular testing. Testing for molecular alterations in the fluid from a pancreatic cyst is currently available and reimbursed by Medicare under certain circumstances. Case series have confirmed that malignant cysts have a greater number and quality of molecular alterations, but no study has been properly designed to identify how the test performs in predicting outcome with regard to need for surgery, surveillance, or predicting interventions leading to improved survival. 40, 210, 211 This adjunct to FNA may provide value in distinct clinical circumstances, such as confirmation of a serous lesion due to a lack of KRAS or GNAS mutation in a macrocystic serous cystadenoma, but its routine use is not supported at the present time.
EUS-FNA provides additional information for characterizing cystic lesions; however, in the absence of positive cytology (rare) or CEA levels at the extremes of the scale, it rarely provides absolute diagnostic certainty for lesion type or its risk of malignancy. This leads to an approach to monitor lesions for change in size or morphology, assuming the lack of worrisome features at initial imaging.
Postoperative mortality and morbidity for patients undergoing surgery for pancreatic cysts. Although patients with pancreatic cysts may harbor malignancy, the only approach to ensure the cyst is not malignant is to resect that portion of the pancreas. However, surgery to resect a pancreatic cyst has associated risks of morbidity and mortality, and it is important to balance potential benefits with potential harms. There has been no systematic review of the harms of pancreatic surgery related to resection of cysts. Given the limited data, we were unable to conduct a systematic review of this topic; however, a comprehensive search of the literature and data extraction for this technical review was performed.
We identified 77 studies evaluating 5790 patients that reported data on morbidity and/or mortality related to surgery performed for resection of pancreatic cysts. 131-134,139,141-143,146,147,153,160,167,170,171,174,175,187 ,191,192,194, 212-245 The characteristics of the studies are shown in Supplementary Table 1 .
There were 74 studies that reported data on mortality involving 5484 patients. 9 , 32,55,61,63,65,70,80,82,83,85,92,93,96,98,   106,112,114,116,120,131-134,139,141-143,146,147,153,160,167,170,171,174 , 175,187,191,192,194,212-225,227-245 There was significant heterogeneity between studies in regard to mortality rates (Cochran Q test ¼ 155 [df ¼ 73]; P < .0001; I 2 ¼ 53%; 95% CI, 37%-64%) with an overall mortality rate of 2.1% (95% CI, 1.5%-2.7%) using a random effects model. There was statistically significant funnel plot asymmetry (Begg-Mazumdar test: Kendall s-b ¼ 0.49; P < .0001), suggesting publication bias or other small study effects. This suggests that the overall mortality is probably underestimated because the overall result is driven by small studies with no mortality. Furthermore, the majority of studies are reported from centers of excellence with high volumes of pancreatic surgery, where outcomes are likely to be better. The national mortality rate in the United States is therefore likely to be >2.3%. Indeed, it is important to note that the SEER database, which contributed 729 US patients to this review, reported an overall mortality of 6.6%, which was no different from that for pancreatic surgery for standard adenocarcinoma of the pancreas. 216 A total of 49 studies involving 3392 patients reported data on morbidity after surgery for pancreatic cysts. 32, 55, 61, 70, 80, 91, 92, 93, 120, 132, 133, 139, 142, 143, 153, 167, 170, 171, 174, 187, 191, 192, 194, 213, 215, 217, 218, 219, 220, 222, 223, 225, 226, 232, 233, 235, 236, 238, 240, 242, 243 Where possible, we restricted data to that related to major events, such as formation of a pancreatic fistula. If the investigators only reported events, we assumed that these did not happen in the same patient when the events were rare (<25%) but did not make this assumption when they were common. There was significant heterogeneity between studies in regard to morbidity rates (Cochran Q test ¼ 403 [df ¼ 48]; P < .0001; I 2 ¼ 88%; 95% CI, 85%-90%), with an overall morbidity rate of 30% (95% CI, 25%-35%) using a random effects model. However, there was no statistically significant funnel plot asymmetry (Begg-Mazumdar test: Kendall s-b ¼ 0.08; P ¼ .41), suggesting there was no publication bias or other small study effects. There is substantial variation between study results, and the reasons for this are not clear. Some will relate to different thresholds for the investigators describing an event as a complication or a major complication.
Patients with pancreatic cysts who are surgical candidates but do not have features that would warrant resection should undergo surveillance with MRI every 1 to 2 years. No cohort studies have analyzed the impact of surveillance and subsequent surgical intervention on the risk of pancreatic cancer among patients with cystic lesions. Given the very low rate of overall malignancy development, it is clear that surveillance imaging in patients should be limited to those who can benefit from major pancreatic resections should the lesion develop cancer. Given the mortality and morbidity of pancreatic resections, this careful determination should be assessed for each patient. Patients who are not surgical candidates because of age or severe comorbidities should not undergo surveillance. However, if the patient is reasonably fit, our review suggests that surveillance once per year or once every 2 years may be prudent, although the evidence base for this is limited.
The imaging modality and frequency of surveillance imaging has also not been subjected to informative studies in the literature. Current guidelines suggest annual (or more frequent) surveillance, particularly for lesions near a size cutoff associated with malignancy (3 cm). 6 These recommendations are not evidence based and should be individualized for each patient. Although the literature contains reports of small lesions harboring malignancy, the vast number of these lesions mandates a rational approach to patient care. Because cancer is rarely found in patients with resected lesions, these size recommendations are likely to be modified upward, particularly as patients age and the mortality benefit of surgery remains undefined.
Although more costly than CT and EUS, MRI in expert hands offers lack of radiation and is an ideal surveillance modality. EUS can be used in those with claustrophobia who require anesthesia for MRI because they are generally equivalent (and can be complementary) and similarly invasive under these circumstances.
Incidence of invasive malignancy in follow-up of pancreatic cysts. International consensus guidelines on the management of pancreatic cysts have suggested followup of cysts that do not have concerning features. 6, 127, 246 The frequency of follow-up depends on the size of the cyst. Guidelines generally do not address whether surveillance can be discontinued at any stage. This has important implications because it could reduce the cost of surveillance of pancreatic cysts if this is not a lifelong commitment. However, it is important to evaluate the risk of malignant progression for pancreatic cysts in determining the interval and duration of surveillance. We have suggested that the risk of developing malignancy is low based on population data, with a lifetime risk of <1% provided the cyst has no concerning features at presentation. The overall risk of malignancy in cysts identified on imaging but not resected remains unclear. We conducted a systematic review of the literature to answer this question.
The search strategy identified 102 potentially relevant reports, of which 62 were eligible for this systematic review. 24, [40] [41] [42] 44, 45, [47] [48] [49] 51, 53, 57, 68, 73, 195, Overall, there were 154 invasive malignancies in 10,496 patients with a median of 34,460 patient-years of follow-up. Studies were from Japan, Italy, the United States, Korea, France, the United Kingdom, and Israel, and all were retrospective case series. The characteristics of the patients are summarized in Supplementary Table 2 .
Follow-up of general pancreatic cystic lesions seen on imaging. There were 22 case series predominantly from the United States and Japan. 24 showing a greater proportion with invasive cancer, suggesting publication bias or other small study effects. The proportion of cases developing invasive malignancy is estimated at 0.72% per year (95% CI, 0.48-1.08). This is higher than predicted from the population-based data, but our analysis included all pancreatic cysts, not just suspected IPMNs, and this may explain the higher risk seen in this review of the literature.
Follow-up of suspected serous cystic neoplasms seen on imaging. There were 3 case series from Italy and Canada that evaluated pancreatic cystic lesions that were believed to be serous cystic lesions on imaging. [237] [238] [239] Overall, no invasive cancers were observed in 276 patients during 1551 patient-years of follow-up.
This systematic review suggests that the overall rate of conversion to invasive cancer is low and for pancreatic cysts in general is approximately 0.24% per year. The rate of conversion is highest for IPMN but this may be an overestimate as the outliers with the highest conversion rates 61, 120, 132, 216 were somewhat unclear on whether initial cancer cases had been excluded from the cohort or were retrospective and designed to show risk factors of neoplastic progression where we suspect that the case series were enriched with cancer cases to ensure their analyses had sufficient power.
The limitations of this systematic review are related to the quality of the underlying studies. All were retrospective case series, and some presented information whereby it was unclear which patients had invasive malignancy. Whenever this was unclear, worst case scenario assumptions were made. The follow-up of patients was often poorly described, and often the median follow-up time was given; for calculation purposes, we assumed that this was similar to the mean.
Patients with pancreatic cysts undergoing surveillance with no or minimal change in the characteristics of the cyst over a 5-year period should have surveillance discontinued. When to discontinue surveillance is not defined by the current literature, which indicates a very slow progression to malignancy in a population with mortality defined by age and other comorbidities. It seems reasonable to perform imaging in selected patients for up to 4 years and discontinue surveillance if there is no change in size, but this area of uncertainty would benefit from additional study.
Our data suggest that the rate of progression to invasive cancer is very low, and this is consistent with our earlier analysis evaluating the risk of cysts progressing to invasive cancer from the systematic review of the prevalence of pancreatic cysts and US population statistics on cystic adenocarcinoma. Furthermore, the vast majority of surgical resections in these case series were performed within the first 2 years of surveillance. Therefore, it may be reasonable to propose extending the surveillance period to 4 years. If there has been no significant change in the characteristics of the cyst over that period, then the probability the patient will have invasive cancer is very low and it is therefore reasonable to discontinue surveillance. We realize that this approach may be controversial; however, based on the analysis of this review showing the low rate of progression of pancreatic cysts to malignancy, we believe that this view is evidence based, although the evidence is weak. Of course, such decisions also need to be made on an individual basis; there are circumstances in which further surveillance beyond 4 years may be warranted, particularly for presumed mucinous lesions in fit patients younger than 70 years of age and in patients who may have an equivocal change in cyst appearance and/or size.
Patients with pancreatic cysts that have concerning features should be offered surgical resection. The selection of patients with pancreatic cysts for surgical resection continues to be a source of controversy in the absence of confirmed malignancy. This technical review has identified major gaps in the literature to define evidence-based decision making in the management of pancreatic cysts. Given the lack of data to support a survival benefit for cyst resection, the approach to proceed with a major pancreatic resection whenever a mucinous lesion is found requires reevaluation. The ability of imaging to accurately define malignancy is poor, and indicating surgery based on size alone or a presumed nodule on imaging will subject many low-risk patients to surgery, along with a significant risk of immediate postoperative morbidity and mortality and uncertain longterm benefits.
The surgical dogma that all MCNs should be resected is not supported by our literature review. Unfortunately, we cannot make definitive recommendations on when surgery should be offered to patients with pancreatic cysts. It would be reasonable to offer surgical resection if there are concerning features that prompted the decision to evaluate the patient with EUS-FNA and the results showed malignant cells on cytology and worrisome imaging features. It is also reasonable to offer surgery if there are more than one of 3 features (size >3 cm, dilated pancreatic duct, or solid component to the cyst) that suggest concern regarding malignancy. Thus, a cyst >3 cm alone should usually not warrant surgical resection; however, a large cyst combined with a dilated pancreatic duct may indicate that there is enough increased risk to justify surgery. We should emphasize that there is little evidence that combined risk factors are additive or synergistic, but we support this simply based on expert opinion. 5, 6 Another issue that should be considered with regard to offering resection is the age and health of the patient. Age is a particular issue that argues both for and against offering resection. Young patients are usually healthier and are likely to live for many years, so any risk of cancer over time is likely to increase. On the other hand, on a population level, their pretest probability of having malignancy is much lower, so this makes the positive predictive value of any of the previously described tests even lower. Although the anxiety and cost of long-term monitoring may sway patients and providers to a surgical intervention, careful consideration of the risks and benefits outlined in this review should be undertaken.
Surgery for symptomatic patients is another category where the evidence remains unclear. Offering surgery to symptomatic patients may seem reasonable, but again the evidence base for this is weak. Many case series have shown that symptoms improve after resection, but undergoing surgery is likely to have a strong placebo response and follow-up of these cohorts over long periods is limited. Given that resection carries a significant risk of morbidity and mortality, the literature review does not support surgical resection on the basis of symptoms alone; instead, symptoms should be taken into consideration with other concerning features of the cyst that may tip the balance of benefits versus harm in favor of offering resection. Such decision making should be performed by a multidisciplinary team of physicians.
Survival after resection of an invasive/malignant pancreatic cyst. We have reviewed the potential harms of resection of pancreatic cysts as well as their malignant potential. It is also important to establish the benefits of removing a pancreatic cyst. There is the potential benefit of preventing a cyst from becoming malignant. The risk of this is likely to be very low in benign lesions, but there is likely to be some benefit for lesions with HGD. Unfortunately, quantifying this benefit is difficult because there are no data on the natural history of cysts with HGD. This is therefore very difficult to determine.
Another benefit is that early removal of an invasive malignant cyst before spread of the lesion may lead to long-term survival of the patient. The literature was reviewed to address this question. Studies with <20 patients and that combined invasive cancer and HGD were excluded. Reports that did not provide 5-year survival data for patients with invasive cancer (either overall or disease-free) were also excluded. We identified 37 studies evaluating 3842 patients. 16 Using a simple average, the overall 5-year survival is 28%. This figure is similar to the most recent SEER data on survival after surgery for a malignant cyst. 295 This is better than survival for standard pancreatic adenocarcinomas but is still disappointing. There was, however, one clear outlying low value reported from early SEER data that evaluated IPMNs treated with surgery from 1983 to 1991. 301 If this study were excluded on the basis that imaging techniques were not as sophisticated for that period, then the 5-year survival rate increases to 36.5%. This is still disappointing but at least more optimistic for the patient. However, there is a major concern that any apparent benefit of survival may simply reflect lead and/or length time bias. Indeed, the few studies that did report survival longer than 5 years would strongly suggest that lead time bias was a factor because mortality for IPMNs approached that of standard pancreatic adenocarcinomas with longer follow-up. There is only one study that reported on 20 invasive MCNs. 16 The overall survival in this small group was 33%, which does not appear better than results for IPMNs.
Patients should undergo annual surveillance with MRI after surgical resection if the resected cyst shows evidence of dysplasia or malignancy. No studies have tested the value of surveillance after pancreatic resection for a precancerous lesion. Case series have supported the concept of a field defect in such patients with IPMNs who may develop tumors due to continued exposure to risk factors (such as alcohol or smoking) as well as a genetic background promoting tumor development. No studies define the outcome of such an approach or define the optimal imaging modality and its frequency. It seems reasonable to follow the principles of surveillance noted in the preceding text. However, given that such patients likely have a much higher long-term risk of malignancy, discontinuation of surveillance cannot be recommended and should commence when the patient is no longer a candidate for surgical resection. If nonsurgical treatment of such lesions becomes a viable alternative providing curative potential, these considerations will change.
Patients should not be offered surveillance after surgical resection if the resected cyst shows no evidence of dysplasia. Again, there is no evidence for this group of patients. However, if the resection shows a simple mucinous or serous cyst with no evidence of dysplasia, then there is unlikely to be a field change and the overall risk of malignancy in this group of patients is likely to be very low. Given that the risk of cystic lesions progressing is low and the patient is currently free of any concerning lesion, it is not appropriate to offer continued surveillance. This would only add cost to the health care system and anxiety for the patient with little likelihood of any longterm benefit.
Bringing Together the Findings From the Technical Review
This review of the literature suggests that pancreatic cysts are common in the general population and the proportion of cysts found to have invasive malignancy at surgery is relatively modest. Malignant transformation is rare in pancreatic cysts that are followed up. The pooled estimates from this review of the literature are subject to some uncertainty, so it is important to evaluate whether the figures outlined in this review are consistent with what would be predicted from the accuracy of diagnostic tests applied to a disorder that is common in the population (pancreatic cysts) with an serious outcome that is rare (pancreatic adenocarcinoma).
A well-known characteristic of the performance of a test is that the positive predictive value decreases and the negative predictive value increases as the disease becomes rarer, despite the sensitivity and specificity of the test being constant 304 (Table 7 ). This review suggests that pancreatic malignancy is rare in a cyst, so it is predicted that the negative predictive value of any strategy that is applied will Figure 1 . Receiver operator curve for the diagnosis of upper gastrointestinal malignancy using alarm symptoms, clinical opinion, or computer models applied to symptom questionnaires. 305 be high but the positive predictive value (ie, the probability that the cyst is malignant) will be low. Another area of uncertainty is the actual performance of an overall strategy of following up a pancreatic cyst and the multifactorial decision-making process to decide to operate. Faced with a disorder that is common, a serious outcome that is rare, and a test that is not particularly accurate, clinicians opt for a strategy that is highly specific and not very sensitive to maximize their chances of ruling a disease in. For example, a systematic review of clinicians trying to diagnose upper gastrointestinal malignancy based on clinical features have a specificity of 97% but a sensitivity of only 29%. 305 In contrast, computer models that attempt to predict malignancy have a high sensitivity, so that few cancers are missed, but a low specificity (Figure 1) . 305 Clinicians have a specificity of 97% and sensitivity of 29% when deciding to refer a patient for an endoscopy to rule out upper gastrointestinal malignancy. When deciding to perform a pancreatic resection, we would expect even more caution and an even higher specificity at the expense of sensitivity. We have modeled this based on a prevalence of invasive malignancy of 0.25%, which was the highest estimate from the systematic review of the population with cysts and extrapolation from the SEER database. We applied 99.75% specificity and 17.5% sensitivity to a prevalence of 0.25%, resulting in a 15% probability that a cyst will harbor invasive malignancy. Our technical review identified 27 studies evaluating 2796 patients undergoing surgical resection of pancreatic cysts and found that 15% had invasive malignancy. Conversely, if a decision is made to simply follow up the cyst with the same test characteristics described in the preceding text, then we can predict that 0.21% of malignant cysts will be missed. This is similar to our technical review, which identified 22 case series that evaluated 6240 patients for a median follow-up of 18,079 years and estimated that 0.24% developed malignancy.
This modeling adds face validity to our estimates. It is possible that the risk of malignancy in a cyst varies modestly from our predictions but is unlikely to be dramatically different, because it would then not be possible to model the test accuracy to the findings of the literature review.
Discussion
In this technical review, we attempted to evaluate the evidence for diagnosing and managing pancreatic cysts. Unfortunately, there is insufficient evidence to make definitive recommendations based on defined measures of risk and patient outcomes (survival benefit).
The approach to the patient with a pancreatic cystic lesion begins with a detailed history and consideration of the differential diagnosis to assess the risk of malignancy. A history that suggests prior pancreatitis or trauma is important because this would increase the likelihood that the lesion is a pseudocyst without malignant potential. In the absence of a history of pancreatitis or trauma, a pseudocyst is unlikely and the concern of a cystic neoplasm is paramount. In general, patients with symptomatic lesions should be evaluated by a multidisciplinary team of physicians to determine if surgical resection is indicated based on symptoms and other findings, weighing the likelihood of malignancy against the risk of surgery. If preoperative characterization of the lesion will change management, EUS and/or FNA for cytological analysis and fluid analysis may provide information of diagnostic and prognostic value. Risk stratification should occur during the initial evaluation, because our analysis suggests that progression is rare.
For patients who have benign-appearing lesions with low-risk features on imaging, a decision regarding the patient's willingness to undergo observation of the lesion should be developed in collaboration with a pancreatic surgeon. In many circumstances, surveillance with noninvasive imaging, typically MRI, and selected use of EUS with or without FNA with cytological analysis and measurement of fluid will allow watchful waiting of a presumed mucinous lesion, including both MCNs and branch duct IPMNs. This approach clearly represents a trade-off of delayed surgery and a low risk of progression to malignancy with the risk of morbidity and mortality associated with surgery; however, given the high prevalence of patients with pancreatic cysts and the low rate of malignant transformation over time, this appears to be the most prudent approach to provide patients with the best overall survival. Given the lack of clear, convincing data, management of patients with pancreatic cysts should be individualized, incorporating the data and recommendations presented in this review along with the clinical judgment of an experienced multidisciplinary team.
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